Literature DB >> 18430073

Male reproductive health after childhood cancer.

P M Lähteenmäki1, M Arola, J Suominen, T T Salmi, A M Andersson, J Toppari.   

Abstract

AIM: Twenty-five male patients were investigated to elucidate the correlation of semen parameters and other related parameters in the assessment of spermatogenesis after childhood cancer treatment.
METHODS: Evaluation of given cancer treatment, anthropometric and testicular size measurements, semen analysis, and measurement of gonadotrophins, testosterone, sex hormone-binding globulin (SHBG), and inhibin B were performed according to a protocol.
RESULTS: Median (range) sperm concentration (SC) was 35.5 (0-273)x10(6)/mL, and percentage of motile sperm 56 (0-86)%. Testicular size (r=0.73, p<0.001) and the level of inhibin B (r=0.66, p<0.001) correlated strongly to SC. SC correlated negatively to FSH (r=0.46, p=0.03). Only testicular size predicted SC significantly (p=0.03). Inhibin B showed highest area under ROC curve (0.83, 95%CI 0.67-0.99) in showing SC<20x10(6)/mL. Body mass index (BMI) did not correlate with SC, but negative correlation between BMI and SHBG was found (r=-0.41, p=0.04).
CONCLUSION: Although semen analysis is a useful instrument for fertility assessment in men, it is often difficult to get these samples from childhood cancer survivors. Thus, indirect methods are needed in prediction of possible sperm count impairment in postpubertal adolescents after cancer treatment. When combined with the data on testicular size and follicle-stimulating hormone (FSH) level, inhibin B gives valuable addition to the estimations of spermatogenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18430073     DOI: 10.1111/j.1651-2227.2008.00784.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  6 in total

1.  Effect of cranial irradiation on sperm concentration of adult survivors of childhood acute lymphoblastic leukemia: a report from the St. Jude Lifetime Cohort Study†.

Authors:  Daniel M Green; Liang Zhu; Mingjuan Wang; Wassim Chemaitilly; DeoKumar Srivastava; William H Kutteh; Raymond W Ke; Charles A Sklar; Ching-Hon Pui; Larry E Kun; Raul C Ribeiro; Leslie L Robison; Melissa M Hudson
Journal:  Hum Reprod       Date:  2017-06-01       Impact factor: 6.918

2.  Oncofertility resources at NCI-designated comprehensive cancer centers.

Authors:  Marla L Clayman; Maya M Harper; Gwendolyn P Quinn; Joyce Reinecke; Shivani Shah
Journal:  J Natl Compr Canc Netw       Date:  2013-12-01       Impact factor: 11.908

3.  Lack of specificity of plasma concentrations of inhibin B and follicle-stimulating hormone for identification of azoospermic survivors of childhood cancer: a report from the St Jude lifetime cohort study.

Authors:  Daniel M Green; Liang Zhu; Nan Zhang; Charles A Sklar; Raymond W Ke; William H Kutteh; James L Klosky; Sheri L Spunt; Monika L Metzger; Fariba Navid; DeoKumar Srivastava; Leslie L Robison; Melissa M Hudson
Journal:  J Clin Oncol       Date:  2013-02-19       Impact factor: 44.544

4.  Inhibin B and anti-Müllerian hormone as markers of gonadal function after hematopoietic cell transplantation during childhood.

Authors:  Sylvie Laporte; Ana-Claudia Couto-Silva; Séverine Trabado; Pierre Lemaire; Sylvie Brailly-Tabard; Hélène Espérou; Jean Michon; André Baruchel; Alain Fischer; Christine Trivin; Raja Brauner
Journal:  BMC Pediatr       Date:  2011-02-25       Impact factor: 2.125

5.  Testicular Function of Childhood Cancer Survivors: Who Is Worse?

Authors:  Ylenia Duca; Andrea Di Cataldo; Giovanna Russo; Emanuela Cannata; Giovanni Burgio; Michele Compagnone; Angela Alamo; Rosita A Condorelli; Sandro La Vignera; Aldo E Calogero
Journal:  J Clin Med       Date:  2019-12-13       Impact factor: 4.241

Review 6.  Follicle Stimulating Hormone is an accurate predictor of azoospermia in childhood cancer survivors.

Authors:  Thomas W Kelsey; Lauren McConville; Angela B Edgar; Alex I Ungurianu; Rod T Mitchell; Richard A Anderson; W Hamish B Wallace
Journal:  PLoS One       Date:  2017-07-20       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.